González-Rodríguez M, Guerra-Soto AJ, Corona-Sánchez EG, Rocha-Muñoz AD, Díaz-González EV, González-López L

Language: Spanish
References: 44
Page: 106-113
PDF size: 410.73 Kb.

ABSTRACT

Ankylosing spondylitis (AS) is an autoimmune, progressive, systemic, inflammatory and disabling disease. Its prevalence in Mexico is of 0.9% in the general population. It affects men the most, in a 5:1 ratio; the average age of onset is 15 to 40 years old. Its etiology is multifactorial; among the main agents leading to its development are genetic and environmental components.

REFERENCES

1. Khan MA. Ankylosing spondylitis: clinical aspects. In: Calin A, Taurog JD, editors. The spondylarthritides. Oxford University Press; 1998. pp. 27-40.

2. Burgos-Vargas R et al. Epidemiology of spondyloarthritis in Mexico. Am J Med Sci. 2011; 341 (4): 298-300.

3. Calin A et al. Clinical history as a screening test for ankylosing spondylitis. JAMA: the journal of the American Medical Association. 1977; 237 (24): 2613-2614.

4. Morales-Romero J et al. La atención médica en reumatología en un hospital de segundo nivel de atención. Rheumatol Clin. 2005; 1: 87-94.

5. Sieper J et al. Ankylosing spondylitis: an overview. Ann Rheum Dis. 2002; 61 (Suppl 3): III8-18.

6. Hochberg MC et al. Chapter 103: Clinical features of ankylosing spondylitis. In: Asim KM. Rheumatology. 3rd ed. Londres: Mosby; 2003. pp. 1161-1183.

7. AI-Khonizy W et al. The immunogenetics of the seronegative spondyloarthropathies. Bailliores Clin Rheumatol. 1998; 12 (4): 567-588.

8. Reveille JD. Major histocompatibility genes and ankylosing spondylitis. Best Practice & Research Clinical Rheumatology. 2006; 20: 601-609.

9. Boyle H et al. Breaking the rules: the unconventional recognition of HLA-B27 by CD4+ T lymphocytes as an insight into the pathogenesis of the spondyloarthropathies. Rheumatology. 2003; 42: 404-412.

10. McMichael A et al. HLA-B27: natural function and pathogenic role in spondyloarthritis. Arthritis Res. 2002; 4 (suppl. 3): S153-S158.

11. Bowness P et al. HLA-B27 and disease pathogenesis: new structural and functional insights. Expert Rev Mol Med. 1999; 26: 1-10.

12. Mielants H et al. HLA antigens in seronegative spondylarthropathies. Reactive arthritis and arthritis in ankylosing spondylitis: relation to gut inflammation. J Rheumatol. 1987; 14: 466-471.

13. Todd D et al. The endoplasmic reticulum stress response in immunity and autoimmunity. Nat Immunol Rev. 2008; 8: 663-674.

14. Dinarello CA et al. Proinflammatory and antiinflammatory citokines in rheumatoid arthritis. A primer for clinicians. USA: Amgen; 1999.

15. Tracey KJ. Tumor necrosis factor-alpha. EN: The cytokine handbook. 2nd ed. San Diego CA: Academic Press; 1994. pp. 289-300.

16. Ibelgaufts H. Dictionary of cytokines. 5th ed. New York: VCH; 1995. p. 777.

17. Callard RE et al. The cytokine facts book. New York: Academic Press Inc; 1994. p. 265.

18. Hajeer AH, Hutchinson IV. Influence of TNF-alpha gene polymorphisms on TNF-alpha production and disease. Hum Immunol. 2001; 62: 1191-1199.

19. Braun J et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 1995; 38: 499-505.

20. Aguillón JC et al. Could single-nucleotide polymorphisms (SNPs) affecting the tumour necrosis factor promoter be considered as part of rheumatoid arthritis evolution. Inmunbiology. 2006; 211: 75-84.

21. Wilson AG et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci. 1997; 94: 3195-3199.

22. López CJ. HLA-B27 and the pathogenesis of spondyloarthropathies. Immunology Letters. 2007; 108: 27-33.

23. Haroon N et al. Ankylosing spondylitis: new criteria, new treatments. Bull NYU Hosp Jt Dis. 2010; 68 (3): 171-174.

24. Bennett AN et al. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum. 2008; 58 (11): 3413-3418.

25. Linden SV et al. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984; 27: 361-368.

26. Gratacós J. Manifestaciones extraarticulares y complicaciones de la espondiloartritis anquilosante. Reumatol Clin. 2005; 1 (1): 25-31.

27. Sieper J et al. Early referral recommendations for ankylosing spondylitis (including re-radiographic and radiographic forms) in primary care. Ann Rheum Dis. 2005; 64: 659-663.

28. Khan MA.. Ann Rheum Dis. 2002; 61 (Suppl 3): iii3-iii7.

29. Anderson P. Regulation of TNF-α expression by mRNA binding proteins. Memorias del «ACR Basic Science Symposium». 2000. pp. 192-198.

30. Grell M et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 880 kDa tumor necrosis factor receptor. Cell. 1995; 83: 793-802.

31. Grell M et al. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci USA. 1998; 95: 570-575.

32. Kolliaas G et al. The function of tumor necrosis factor and receptors in models of multi-organs inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Ann Rheum Dis. 1999; 58 (Suppl. I): I32-I39.

33. Andreu JL et al. Terapia anti-TNFα en espondilitis anquilosante, control sintomático y modificación del daño estructural. Reumatol Clin. 2011; 7 (1): 51-55.

34. Primer documento de consenso de la Sociedad Española de Reumatología sobre uso de antagonistas del TNF en las espondiloartritis. Panel de Expertos de la Sociedad Española de Reumatología. Reumatol Clin. 2005; 1: 32-37.

35. Chatham WW. Chapter 42: Traditional disease-modifying antirheumatic drugs: gold compound, d-penicillamine, sulfasalazine, and antimalarials.In: Koopman WJ et al. Arthritis and allied conditions: a textbook of rheumatology. 15th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. pp. 915-944.

36. Braun J et al. Therapy of ankylosing and other spondyloarthritis: established medical treatment, anti TNF-alpha therapy and other novel approaches. Arthritis Red. 2004; 4: 307-321.

37. Orr A, Parker R. Red clover causing symptoms suggestive of methotrexate toxicity in a patient on high-dose methotrexate. Menopause Int. 2013; 19 (3): 133-134.

38. Escalas C et al. Evaluation of the treatment effect of NSAID/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis. Rheumatology (Oxford). 2010; 49: 1317-1325.

39. Guía de Práctica Clínica Uso de Terapia Biológica en Espondilitis Anquilosante del Adulto, México; Secretaría de Salud, 2009.

40. Brandt et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003; 48: 1667-1675.

41. Rudwaleit M et al. Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Ann Rheum Dis. 2005; 64: 1305-1310.

42. Van der Heijde D et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 2008; 58: 1324-1331.

43. Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewé R. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2013. doi: 10.1136/annrheumdis-2013-204317.

44. Shu T, Chen GH, Rong L, Feng F, Yang B, Chen R et al. Indirect comparison of anti-TNF-α agents for active ankylosing spondylitis: mixed treatment comparison of randomized controlled trials. Clin Exp Rheumatol. 2013; 31 (5): 717-722.